Literature DB >> 3190181

Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

J W Stone1, J M Andrews, J P Ashby, D Griggs, R Wise.   

Abstract

The pharmacokinetics of the quinolone lomefloxacin were determined following a single 400-mg oral dose given to each of six male volunteers. Concentrations in serum, urine, and cantharidin-induced inflammatory fluid were determined by a microbiological assay. Samples from two volunteers were also assayed by high-performance liquid chromatography. The mean peak level in serum, 4.7 micrograms/ml, was attained within 1 h of administration. The mean elimination half-life from serum was 7 h. Inflammatory fluid was penetrated rapidly, with a mean peak level of 3.5 micrograms/ml occurring after 2.7 h. The mean recovery of lomefloxacin from urine over 48 h was 76% of the administered dose. There was a minor peak on the high-performance liquid chromatography trace, suggesting a small amount of unidentified metabolite. This was present only in urine; no detectable metabolites were found in serum. This study suggests that either once-daily or twice-daily dosage of lomefloxacin should be sufficient to treat urinary or systemic infections, respectively, caused by susceptible pathogens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190181      PMCID: PMC175908          DOI: 10.1128/AAC.32.10.1508

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  The comparative pharmacokinetics of five quinolones.

Authors:  R Wise; D Lister; C A McNulty; D Griggs; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

4.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

5.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  The pharmacokinetics and tissue penetration of norfloxacin.

Authors:  Z N Adhami; R Wise; D Weston; B Crump
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

7.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

8.  In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; R S Matthews
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  Pharmacokinetics and tissue penetration of orally administered pefloxacin.

Authors:  J M Webberley; J M Andrews; J P Ashby; A McLeod; R Wise
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

10.  The pharmacokinetics and tissue penetration of ofloxacin.

Authors:  M R Lockley; R Wise; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

  10 in total
  26 in total

1.  Pharmacokinetics of lomefloxacin in renally compromised patients.

Authors:  R A Blum; R W Schultz; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

2.  Concentrations of oral lomefloxacin in serum and bronchial mucosa.

Authors:  D R Baldwin; D Honeybourne; J M Andrews; J P Ashby; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Effect of lomefloxacin on the normal oral and intestinal microflora.

Authors:  C Edlund; B Brismar; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

Review 4.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.

Authors:  R Wise; S Jones; I Das; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days.

Authors:  I Gros; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.

Authors:  J Kavi; J Stone; J M Andrews; J P Ashby; R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

8.  Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.

Authors:  C Rustige; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

9.  Dermal microdialysis sampling in vivo.

Authors:  J M Ault; C M Riley; N M Meltzer; C E Lunte
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

Review 10.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.